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Antimicrobial peptides (AMPs) are good candidates to treat burn wounds, a major cause 
of morbidity, impaired life quality and resources consumption in developed countries. 
Tuberculosis (TB), a disease caused by the human pathogen Mycobacterium tuberculosis, 
represents the second world’s deadliest infectious disease, affecting around 9 million 
people worldwide in 2013. Of those, about 1.1 million died from the disease. The potential of 
cathelicin, a human AMP, in the treatment of mycobacteriosis and wound regeneration was 
assessed in pre-clinical trials.
We took advantage of a commercially available hydrogel, Carbopol, a vehicle for topical 
administration that maintains a moist environment within the wound site. We hypothesized 
that the incorporation of LLKKK18 conjugated to dextrin (FDA-approved) would improve the 
healing process in rat burns. Whereas the hydrogel improves healing, LLKKK18 released 
from the dextrin conjugates further accelerates wound closure, and simultaneously 
improving the quality of healing. Indeed, the release of LLKKK18 reduces oxidative stress 
and inflammation (low neutrophil and macrophage infiltration and pro-inflammatory 
cytokines levels). Importantly, it induced a faster resolution of the inflammatory stage 
through early M2 macrophage recruitment. In addition, LLKKK18 stimulates angiogenesis 
(increased VEGF and microvessel development in vivo), potentially contributing to more 
effective transport of nutrients and cytokines. Moreover, LLKKK18 improves the quality of 
the healing tissue, by promoting proper collagen deposition. These findings suggest that 
LLKKK18 holds great potential as a therapeutic approach for burn treatment.
Cathelicidin was encapsulated in hyaluronic acid nanogels and administered in the mice 
deep lung for the treatment of mycobacteriosis. The results obtained will be discussed.
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